ROLE OF MIFEPRISTONE (10MG) IN TREATMENT OF UTERINE MYOMA

Abstract

Objectives: To evaluate the effect of low-dose mifepristone (10 mg) on symptomatic uterine myoma

Study design: Prospective observational study

Materials and methods: hundred women of age 20 to 45 years having symptomatic myoma were selected from gynecology outpatient department and given 10 mg mifepristone once daily continuously for 3 months. Baseline myoma size, volume, their number, position, characteristics, hemoglobin and blood parameters, were taken and Total duration of the treatment was 3 months. Follow-up made at 1st, 3rd and 6th month (3 month after stopping the treatment). At each follow-up improvement in symptoms, PBAC score, VAS score, fibroid size, haemoglobin changes were recorded. 

Statistical analysis: Done by calculating mean, standard deviation, standard error and percentage distribution of variables.

Results: Menorrhagia was the commonest symptom for which patients report to hospital. Mean dominant myoma volume reduced from 62.89 ± 34.69 to 45.34 ± 28.43 (30.11 ± 5.21%) at 3 months and hemoglobin level raised to 19.57% after complete treatment of 3 months. Changes persisted in next 3 months post-treatment follow-up, while hysterectomy was required in 11(11.0%) cases.

Conclusion: Three months treatment of 10 mg mifepristone effectively controls bleeding, reduce myoma volume, improve haemoglobin and reduced hysterectomy in symptomatic myoma cases.

Keywords: Mifepristone, Myoma, Medical treatment, Antiprogesterone.